vs

Side-by-side financial comparison of Limbach Holdings, Inc. (LMB) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $186.9M, roughly 1.7× Limbach Holdings, Inc.). Limbach Holdings, Inc. runs the higher net margin — 6.6% vs -18.2%, a 24.8% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 30.1%). Limbach Holdings, Inc. produced more free cash flow last quarter ($27.9M vs $-133.8M).

Limbach Flugmotoren is a Chinese-owned company based in Germany that produces aircraft engines.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

LMB vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.7× larger
MDGL
$321.1M
$186.9M
LMB
Growing faster (revenue YoY)
MDGL
MDGL
+180.7% gap
MDGL
210.8%
30.1%
LMB
Higher net margin
LMB
LMB
24.8% more per $
LMB
6.6%
-18.2%
MDGL
More free cash flow
LMB
LMB
$161.7M more FCF
LMB
$27.9M
$-133.8M
MDGL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LMB
LMB
MDGL
MDGL
Revenue
$186.9M
$321.1M
Net Profit
$12.3M
$-58.6M
Gross Margin
25.7%
Operating Margin
9.4%
-18.6%
Net Margin
6.6%
-18.2%
Revenue YoY
30.1%
210.8%
Net Profit YoY
25.0%
1.4%
EPS (diluted)
$1.01
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LMB
LMB
MDGL
MDGL
Q4 25
$186.9M
$321.1M
Q3 25
$184.6M
$287.3M
Q2 25
$142.2M
$212.8M
Q1 25
$133.1M
$137.3M
Q4 24
$143.7M
$103.3M
Q3 24
$133.9M
$62.2M
Q2 24
$122.2M
Q1 24
$119.0M
$0
Net Profit
LMB
LMB
MDGL
MDGL
Q4 25
$12.3M
$-58.6M
Q3 25
$8.8M
$-114.2M
Q2 25
$7.8M
$-42.3M
Q1 25
$10.2M
$-73.2M
Q4 24
$9.8M
$-59.4M
Q3 24
$7.5M
$-107.0M
Q2 24
$6.0M
Q1 24
$7.6M
$-147.5M
Gross Margin
LMB
LMB
MDGL
MDGL
Q4 25
25.7%
Q3 25
24.2%
Q2 25
28.0%
Q1 25
27.6%
96.7%
Q4 24
30.3%
Q3 24
27.0%
Q2 24
27.4%
Q1 24
26.1%
Operating Margin
LMB
LMB
MDGL
MDGL
Q4 25
9.4%
-18.6%
Q3 25
7.2%
-39.7%
Q2 25
7.5%
-22.2%
Q1 25
5.9%
-57.8%
Q4 24
9.1%
-64.8%
Q3 24
8.1%
-187.1%
Q2 24
6.7%
Q1 24
5.5%
Net Margin
LMB
LMB
MDGL
MDGL
Q4 25
6.6%
-18.2%
Q3 25
4.8%
-39.8%
Q2 25
5.5%
-19.9%
Q1 25
7.7%
-53.4%
Q4 24
6.9%
-57.5%
Q3 24
5.6%
-172.0%
Q2 24
4.9%
Q1 24
6.4%
EPS (diluted)
LMB
LMB
MDGL
MDGL
Q4 25
$1.01
$-2.55
Q3 25
$0.73
$-5.08
Q2 25
$0.64
$-1.90
Q1 25
$0.85
$-3.32
Q4 24
$0.81
$-2.50
Q3 24
$0.62
$-4.92
Q2 24
$0.50
Q1 24
$0.64
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LMB
LMB
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$11.3M
$198.7M
Total DebtLower is stronger
$30.5M
$339.9M
Stockholders' EquityBook value
$195.7M
$602.7M
Total Assets
$381.1M
$1.3B
Debt / EquityLower = less leverage
0.16×
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LMB
LMB
MDGL
MDGL
Q4 25
$11.3M
$198.7M
Q3 25
$9.8M
$295.7M
Q2 25
$38.9M
$186.2M
Q1 25
$38.1M
$183.6M
Q4 24
$44.9M
$100.0M
Q3 24
$51.2M
$232.7M
Q2 24
$59.5M
Q1 24
$48.2M
$622.5M
Total Debt
LMB
LMB
MDGL
MDGL
Q4 25
$30.5M
$339.9M
Q3 25
$56.3M
$339.8M
Q2 25
$28.4M
$118.4M
Q1 25
$23.7M
$118.0M
Q4 24
$23.6M
$117.6M
Q3 24
$20.5M
$117.1M
Q2 24
$19.7M
Q1 24
$19.4M
$116.1M
Stockholders' Equity
LMB
LMB
MDGL
MDGL
Q4 25
$195.7M
$602.7M
Q3 25
$181.6M
$625.7M
Q2 25
$170.5M
$696.0M
Q1 25
$161.1M
$710.6M
Q4 24
$153.5M
$754.4M
Q3 24
$142.2M
$777.2M
Q2 24
$133.0M
Q1 24
$125.5M
$850.8M
Total Assets
LMB
LMB
MDGL
MDGL
Q4 25
$381.1M
$1.3B
Q3 25
$409.1M
$1.4B
Q2 25
$343.0M
$1.0B
Q1 25
$336.4M
$996.6M
Q4 24
$352.1M
$1.0B
Q3 24
$324.4M
$1.1B
Q2 24
$303.9M
Q1 24
$289.2M
$1.1B
Debt / Equity
LMB
LMB
MDGL
MDGL
Q4 25
0.16×
0.56×
Q3 25
0.31×
0.54×
Q2 25
0.17×
0.17×
Q1 25
0.15×
0.17×
Q4 24
0.15×
0.16×
Q3 24
0.14×
0.15×
Q2 24
0.15×
Q1 24
0.15×
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LMB
LMB
MDGL
MDGL
Operating Cash FlowLast quarter
$28.1M
$-133.5M
Free Cash FlowOCF − Capex
$27.9M
$-133.8M
FCF MarginFCF / Revenue
14.9%
-41.7%
Capex IntensityCapex / Revenue
0.1%
0.1%
Cash ConversionOCF / Net Profit
2.29×
TTM Free Cash FlowTrailing 4 quarters
$41.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LMB
LMB
MDGL
MDGL
Q4 25
$28.1M
$-133.5M
Q3 25
$13.3M
$79.8M
Q2 25
$2.0M
$-47.1M
Q1 25
$2.2M
$-88.9M
Q4 24
$19.3M
$-104.5M
Q3 24
$4.9M
$-67.0M
Q2 24
$16.5M
Q1 24
$-3.9M
$-149.2M
Free Cash Flow
LMB
LMB
MDGL
MDGL
Q4 25
$27.9M
$-133.8M
Q3 25
$12.8M
$79.0M
Q2 25
$1.2M
Q1 25
$11.0K
Q4 24
$18.0M
$-104.7M
Q3 24
$4.6M
$-67.8M
Q2 24
$13.2M
Q1 24
$-6.5M
$-149.5M
FCF Margin
LMB
LMB
MDGL
MDGL
Q4 25
14.9%
-41.7%
Q3 25
7.0%
27.5%
Q2 25
0.8%
Q1 25
0.0%
Q4 24
12.5%
-101.3%
Q3 24
3.4%
-109.0%
Q2 24
10.8%
Q1 24
-5.5%
Capex Intensity
LMB
LMB
MDGL
MDGL
Q4 25
0.1%
0.1%
Q3 25
0.3%
0.3%
Q2 25
0.6%
0.0%
Q1 25
1.7%
0.0%
Q4 24
0.9%
0.2%
Q3 24
0.3%
1.3%
Q2 24
2.7%
Q1 24
2.1%
Cash Conversion
LMB
LMB
MDGL
MDGL
Q4 25
2.29×
Q3 25
1.52×
Q2 25
0.26×
Q1 25
0.22×
Q4 24
1.96×
Q3 24
0.66×
Q2 24
2.77×
Q1 24
-0.52×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LMB
LMB

Owner Direct Relationships Segment$145.0M78%
General Contractor Construction Manager Relationships Segment$41.9M22%

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons